hrcak mascot   Srce   HID

Izvorni znanstveni članak
https://doi.org/10.2478/v10007-009-0028-5

Development and optimization of a sublingual tablet formulation for physostigmine salicylate

NOUSHIN BOLOURCHIAN ; School of Pharmacy, Shahid Beheshti University of Medical Sciences (M.C.), Tehran, Iran
NAGHMEH HADIDI ; School of Pharmacy, Shahid Beheshti University of Medical Sciences (M.C.), Tehran, Iran
SEYED MOHSEN FOROUTAN ; School of Pharmacy, Shahid Beheshti University of Medical Sciences (M.C.), Tehran, Iran
BIJAN SHAFAGHI ; School of Pharmacy, Shahid Beheshti University of Medical Sciences (M.C.), Tehran, Iran

Puni tekst: engleski, pdf (123 KB) str. 301-312 preuzimanja: 2.592* citiraj
APA 6th Edition
BOLOURCHIAN, N., HADIDI, N., FOROUTAN, S.M. i SHAFAGHI, B. (2009). Development and optimization of a sublingual tablet formulation for physostigmine salicylate. Acta Pharmaceutica, 59 (3), 301-312. https://doi.org/10.2478/v10007-009-0028-5
MLA 8th Edition
BOLOURCHIAN, NOUSHIN, et al. "Development and optimization of a sublingual tablet formulation for physostigmine salicylate." Acta Pharmaceutica, vol. 59, br. 3, 2009, str. 301-312. https://doi.org/10.2478/v10007-009-0028-5. Citirano 15.10.2019.
Chicago 17th Edition
BOLOURCHIAN, NOUSHIN, NAGHMEH HADIDI, SEYED MOHSEN FOROUTAN i BIJAN SHAFAGHI. "Development and optimization of a sublingual tablet formulation for physostigmine salicylate." Acta Pharmaceutica 59, br. 3 (2009): 301-312. https://doi.org/10.2478/v10007-009-0028-5
Harvard
BOLOURCHIAN, N., et al. (2009). 'Development and optimization of a sublingual tablet formulation for physostigmine salicylate', Acta Pharmaceutica, 59(3), str. 301-312. https://doi.org/10.2478/v10007-009-0028-5
Vancouver
BOLOURCHIAN N, HADIDI N, FOROUTAN SM, SHAFAGHI B. Development and optimization of a sublingual tablet formulation for physostigmine salicylate. Acta Pharm. [Internet]. 2009 [pristupljeno 15.10.2019.];59(3):301-312. https://doi.org/10.2478/v10007-009-0028-5
IEEE
N. BOLOURCHIAN, N. HADIDI, S.M. FOROUTAN i B. SHAFAGHI, "Development and optimization of a sublingual tablet formulation for physostigmine salicylate", Acta Pharmaceutica, vol.59, br. 3, str. 301-312, 2009. [Online]. https://doi.org/10.2478/v10007-009-0028-5

Sažetak
This study is aimed to design and optimize a sublingual tablet formulation of physostigmine salicylate, an effective drug in Alzheimer’s disease and nerve gas poisoning, by means of the D-optimal experimental design methodology. Polyvinyl pyrrolidone, lactose, starch 1500 and sodium starch glycolate were used in the formulations as independent variables. Tablets were prepared by the direct compression method and evaluated for their physical properties (tablet hardness, disintegration time and friability), which were regarded as responses in a D-optimal design. Due to the significance of the special cubic model for data fitted, compared to other models, it was used to examine the obtained results. Response surface plots were plotted to study the tablet properties and the optimized overlay plot was generated based on the results and targets considered for the responses. After verification of the optimum checkpoint formulations, an optimized formulation was chosen due to its desirable physical properties and closely observed and predicted values. Drug assay, content uniformity of the dosage unit, drug dissolution and accelerated stability studies were done on the optimum formulation as further experiments. All the obtained results complied with the requirements of a sublingual tablet formulation.

Ključne riječi
D-optimal mixture design; physostigmine salicylate; sublingual tablet; stability studies

Hrčak ID: 39311

URI
https://hrcak.srce.hr/39311

[hrvatski]

Posjeta: 3.220 *